<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H9EDD274DE66F4FB1B791D44BAF4908BE" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 5811 IH: Long-Term Opioid Efficacy Act of 2018</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2018-05-15</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 5811</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20180515">May 15, 2018</action-date><action-desc><sponsor name-id="M001166">Mr. McNerney</sponsor> (for himself and <cosponsor name-id="G000568">Mr. Griffith</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act with respect to postapproval study requirements
			 for certain controlled substances, and for other purposes.</official-title></form>
	<legis-body id="H012FC294CC2445DDA013D657C2F7FEE2" style="OLC">
 <section id="id24496B6994594DC1B3531554CE80F69C" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Long-Term Opioid Efficacy Act of 2018</short-title></quote>.</text> </section><section id="H6F705385F4C34D4B84CA5713B284EA11" section-type="subsequent-section"><enum>2.</enum><header>Postapproval study requirements</header> <subsection id="HBB071D6752C34920B23DD1A6D89363FF"><enum>(a)</enum><header>Purposes of study</header><text display-inline="yes-display-inline">Section 505(o)(3)(B) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(o)(3)(B)</external-xref>) is amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H3F88D97EAE21485FBAE7428FB648565B" style="OLC">
 <clause commented="no" id="H9A07F29A984547F1AAAF9E0484EF8BFE"><enum>(iv)</enum><text display-inline="yes-display-inline">To assess a potential reduction in effectiveness or an increase in serious risk of the drug for the conditions of use prescribed, recommended, or suggested in the labeling thereof if—</text>
 <subclause commented="no" id="HA1020E5C3DE64DF98FF4653E283C7E95"><enum>(I)</enum><text display-inline="yes-display-inline">the drug involved—</text> <item commented="no" id="H040339DF62C140529DE6B9DE58E70F0D"><enum>(aa)</enum><text>is or contains a substance for which a listing in any schedule is in effect (on a temporary or permanent basis) under section 201 of the Controlled Substances Act; or</text>
 </item><item commented="no" id="HDA6ACD0113BC4D81931E6225521976A5"><enum>(bb)</enum><text>is a drug that has not been approved under this section or licensed under section 351 of the Public Health Service Act, for which an application for such approval or licensure is pending or anticipated, and for which the Secretary provides notice to the sponsor that the Secretary intends to issue a scientific and medical evaluation and recommend controls under the Controlled Substances Act; and</text>
 </item></subclause><subclause commented="no" id="H0CE198DFB80449F280804507B254D3E9"><enum>(II)</enum><text display-inline="yes-display-inline">the potential reduction in effectiveness or the increase in serious risk could result in the benefits of the drug no longer outweighing the risks.</text></subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H91A50E3451E242FE9120747AEFAF16F2"><enum>(b)</enum><header>Establishment of requirement</header><text display-inline="yes-display-inline">Section 505(o)(3)(C) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(o)(3)(C)</external-xref>) is amended by striking <quote>such requirement</quote> and all that follows through <quote>safety information.</quote> and inserting the following:</text>
				<quoted-block display-inline="yes-display-inline" id="H833F41CAA56544C69B1FC211AAE6A084" style="OLC">
 <text>such requirement—</text><clause id="H2D69DDE65C2846AE9A3D399853300D73"><enum>(i)</enum><text display-inline="yes-display-inline">in the case of a purpose described in clause (i), (ii), or (iii) of subparagraph (B), only if the Secretary becomes aware of new safety information; and</text>
 </clause><clause id="H44D1D7FFFE9A4FC7905D13EB8479C269"><enum>(ii)</enum><text display-inline="yes-display-inline">in the case of a purpose described in clause (iv) of such subparagraph, if the Secretary determines that new effectiveness information exists.</text></clause><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="HB529010AC9EA44838712A77E3D21F51E"><enum>(c)</enum><header>Applicability</header><text display-inline="yes-display-inline">Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(o)(3)</external-xref>) is amended by adding at the end the following new subparagraph:</text>
				<quoted-block display-inline="no-display-inline" id="HE14C3D1AFA42466DBEFC6423C05D9283" style="OLC">
 <subparagraph id="HDAA3676984554ADD9A3232478995930C"><enum>(E)</enum><header>Applicability</header><text display-inline="yes-display-inline">The conduct of a study or clinical trial required pursuant to this paragraph for the purpose specified in subparagraph (B)(iv) shall not be considered a new clinical investigation for the purpose of a period of exclusivity under clause (iii) or (iv) of subsection (c)(3)(E) or clause (iii) or (iv) of subsection (j)(5)(F).</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="HC53B86DF2C954E9799FE2A1A5ADB8D9A"><enum>(d)</enum><header>New effectiveness information defined</header><text display-inline="yes-display-inline">Section 505(o)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(o)(2)</external-xref>) is amended by adding at the end the following new subparagraph:</text>
				<quoted-block display-inline="no-display-inline" id="H94ABD8F6DD054B4F84DF3FFB89436C3F" style="OLC">
 <subparagraph id="H185D900564614293A66EC3F8E6DCC253"><enum>(D)</enum><header>New effectiveness information</header><text display-inline="yes-display-inline">The term <term>new effectiveness information</term>, with respect to a drug that is or contains a controlled substance for which a listing in any schedule is in effect (on a temporary or permanent basis) under section 201 of the Controlled Substances Act, means new information about the effectiveness of the drug, including a new analysis of existing information, derived from—</text>
 <clause id="HD4FF528AE9CE4ECD97FDB4D271944C7E"><enum>(i)</enum><text>a clinical trial; an adverse event report; a postapproval study or clinical trial (including a study or clinical trial under paragraph (3));</text>
 </clause><clause id="HE2203AD6351340A09F5FD8D0AC9A45AF"><enum>(ii)</enum><text>peer-reviewed biomedical literature;</text> </clause><clause id="H0D2C77198D1B48AA902644A3A02DF8F5"><enum>(iii)</enum><text>data derived from the post­mar­ket risk identification and analysis system under subsection (k); or</text>
 </clause><clause id="HDFA77D98D243499A9BD7EB520FF8719C"><enum>(iv)</enum><text>other scientific data determined to be appropriate by the Secretary.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block> </subsection><subsection id="HBCD1F1E3D81449BBB2D9D7AC422B36E8"><enum>(e)</enum><header>Conforming amendments with respect to labeling changes</header><text display-inline="yes-display-inline">Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(o)(4)</external-xref>) is amended—</text>
 <paragraph id="H36178DDF45874768BA59FB3A10AAA726"><enum>(1)</enum><text>in subparagraph (A)—</text> <subparagraph id="H396CBD7254E84A0DA804510F529D97CF"><enum>(A)</enum><text>in the heading, by inserting <quote><header-in-text level="subparagraph" style="OLC">or new effectiveness</header-in-text></quote> after <quote><header-in-text level="subparagraph" style="OLC">safety</header-in-text></quote>;</text>
 </subparagraph><subparagraph id="HD1A8FDA9B6DF4754BB24C696DFD80B47"><enum>(B)</enum><text>by striking <quote>safety information</quote> and inserting <quote>new safety information or new effectiveness information such</quote>; and</text> </subparagraph><subparagraph id="H94A99EAD9C844424A68A7F7C804BAB40"><enum>(C)</enum><text>by striking <quote>believes should be</quote> and inserting <quote>believes changes should be made to</quote>;</text>
 </subparagraph></paragraph><paragraph id="HF27791BFF3524DA58F5B05E5A8D03350"><enum>(2)</enum><text display-inline="yes-display-inline">in subparagraph (B)(i)—</text> <subparagraph id="H61BF404132DC4232BD1118CEEFFE0103"><enum>(A)</enum><text>by striking <quote>new safety information</quote> and by inserting <quote>new safety information or new effectiveness information</quote>; and</text>
 </subparagraph><subparagraph id="H10C3391344084F2DBE96F55CB44527F6"><enum>(B)</enum><text>by inserting <quote>indications,</quote> after <quote>boxed warnings,</quote>;</text> </subparagraph></paragraph><paragraph id="HC422BEC9294949A0AE33DBBB0A920E14"><enum>(3)</enum><text>in subparagraph (C), by inserting <quote>or new effectiveness information</quote> after <quote>safety information</quote>; and</text>
 </paragraph><paragraph id="H5FB44A7B939A4FCC82E20F2C5833ECA5"><enum>(4)</enum><text display-inline="yes-display-inline">in subparagraph (E), by inserting <quote>or new effectiveness information</quote> after <quote>safety information</quote>.</text> </paragraph></subsection><subsection id="HBB08E338065A4598A96C528E3703B71B"><enum>(f)</enum><header>Rule of construction</header><text display-inline="yes-display-inline">Nothing in the amendments made by this section shall be construed to alter, in any manner, the meaning or application of the provisions of paragraph (3) of section 505(o) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(o)</external-xref>) with respect to the authority of the Secretary of Health and Human Services to require a postapproval study or clinical trial for a purpose specified in clauses (i) through (iii) of subparagraph (B) of such paragraph (3) or paragraph (4) of such section 505(o) with respect to the Secretary’s authority to require safety labeling changes. <italic></italic></text>
			</subsection></section></legis-body></bill>


